Evidence map›Paper›PMID 29707975›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents.

Wagdy M Eldehna, Reem I Al-Wabli, Maha S Almutairi, Adam B Keeton, Gary A Piazza, Hatem A Abdel-Aziz, Mohamed I Attia

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Identification of sulphonamide-tetheredJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Wagdy M Eldehnaa Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Kafrelsheikh University , Kafrelsheikh , Egypt.
Reem I Al-Wablib Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
Maha S Almutairib Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
Adam B Keetonc Department of Oncologic Sciences and Pharmacology , Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama , Mobile , AL , USA.
Gary A Piazzac Department of Oncologic Sciences and Pharmacology , Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama , Mobile , AL , USA.
Hatem A Abdel-Azizd Department of Applied Organic Chemistry , National Research Centre , Giza , Egypt.
Mohamed I Attiab Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
King Saud University · SAKafrelsheikh University · EGNational Research Centre · EGUniversity of South Alabama · USUSA Mitchell Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In connection with our research program on the development of novel indolin-2-one-based anticancer candidates, herein we report the design and synthesis of different series of hydrazonoindolin-2-ones 3a-e, 5a-e, 7a-c, and 10a-l. The synthesised derivatives were in vitro evaluated for their anti-proliferative activity towards lung A-549, colon HT-29, and breast ZR-75 human cancer cell lines. Compounds 5b, 5c, 7b, and 10e emerged as the most potent derivatives with average IC

Indexed as

Antineoplastic AgentsCell CycleCell LineCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansIndolesMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsIndolesindolin-2-onecell cycle progressionindolin-2-onemultidrug resistant cancer cell linesretinoblastoma (Rb) proteinSynthesis

Identifiers

PMID29707975
PMCPMC7011955
OpenAlexW2800422355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.